Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.78

Mkt cap

188K

Volume

27M

High

0.96

P/E Ratio

N/A

52-wk high

138.00

Low

0.56

Div yield

N/A

52-wk low

0.56

In Monday's intraday session, several healthcare stocks experienced significant movements. OneMedNet (ONMD) saw a 175.1% increase, while Palisade Bio (PALI) and NexImmune (NEXI) rose by 106.48% and 84.48%, respectively. FibroGen (FGEN), Atreca (BCEL), and Vivos Therapeutics (VVOS) also posted gains. Conversely, Panbela Therapeutics (PBLA), Processa Pharma (PCSA), Bullfrog AI Hldgs (BFRG), Inspire Veterinary (IVP), Corbus Pharmaceuticals (CRBP), and TC BioPharm (TCBP) experienced declines.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 5:31 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Corbus Pharmaceuticals (CRBP) saw a massive increase of 309.1%, while Aclarion (ACON) rose by 67.82%. Inspire Veterinary (IVP), Panbela Therapeutics (PBLA), Inhibikase Therapeutics (IKT), and Vera Therapeutics (VERA) also posted gains. Conversely, Onconetix (ONCO), Processa Pharma (PCSA), Evaxion Biotech (EVAX), Jin Medical International (ZJYL), Acutus Medical (AFIB), and TC BioPharm (TCBP) experienced declines, with ONCO leading the losses at 33.7%.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 5:31 pm

Tellurian Inc. (NASDAQ:TELL) shares surged over 16% in pre-market trading on reports of hiring Lazard for a potential sale. Other stocks showed significant movement in pre-market trading, with various gainers and losers listed, including notable declines in Intel Corporation (NASDAQ:INTC) after a weak Q1 forecast, and Western Digital Corporation (NASDAQ:WDC) despite better-than-expected earnings.

Portfolio Pulse from Avi Kapoor

January 26, 2024 | 12:58 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. Cadrenal Therapeutics (CVKD), vTv Therapeutics (VTVT), Passage Bio (PASG), TC BioPharm (TCBP), Brainstorm Cell (BCLI), and Kazia Therapeutics (KZIA) were gainers, with increases ranging from 5.62% to 8.5%. On the losing side, Adicet Bio (ACET), Adagene (ADAG), Bone Biologics (BBLG), TransCode Therapeutics (RNAZ), Cabaletta Bio (CABA), and DocGo (DCGO) saw declines between 5.49% and 22.1%.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 9:31 pm

Coherus BioSciences, Inc. (NASDAQ:CHRS) shares surged 22.1% in pre-market trading following the announcement of a $170 million all-cash deal to divest its ophthalmology franchise to Sandoz. Other stocks experienced significant movement in pre-market trading, with notable gainers including Northann Corp. (NYSE:NCL), HNR Acquisition Corp (NYSE:HNRA), and Porch Group, Inc. (NASDAQ:PRCH). Conversely, companies like B. Riley Financial, Inc. (NASDAQ:RILY) and Agrify Corporation (NASDAQ:AGFY) saw their shares decline. Archer-Daniels-Midland Company (NYSE:ADM) also dropped after announcing an interim CFO and adjusted EPS expectations.

Portfolio Pulse from Avi Kapoor

January 22, 2024 | 1:21 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Mesoblast (MESO) saw a 22.1% increase, while Sangamo Therapeutics (SGMO) rose by 20.27%. Telesis Bio (TBIO) and INVO Bioscience (INVO) also saw gains of 19.27% and 17.43%, respectively. Coherus BioSciences (CHRS) and TC BioPharm (TCBP) shares increased as well. On the downside, Esperion Therapeutics (ESPR) fell by 17.7%, Adial Pharmaceuticals (ADIL) by 15.47%, Accelerate Diagnostics (AXDX) by 10.91%, Alaunos Therapeutics (TCRT) by 9.47%, Nuwellis (NUWE) by 9.12%, and MorphoSys (MOR) by 8.7%.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 1:06 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Moleculin Biotech, Evoke Pharma, TC BioPharm, CNS Pharma, Atreca, and ASLAN Pharma were among the gainers, with increases ranging from 5.94% to 8.7%. Conversely, Savara, MyMD Pharmaceuticals, Alector, Enliven Therapeutics, Estrella Immunopharma, and Trevena were the losers, with declines between 4.97% and 11.9%. The market capitalizations of these companies vary, with some below $10 million and others exceeding $500 million.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 9:31 pm

TC BioPharm (NASDAQ:TCBP), a clinical stage biotechnology company, has regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained a closing bid price of $1.00 or more for at least 10 consecutive business days, satisfying Nasdaq's condition for continued listing on the Nasdaq Capital Market. Previously, on June 22, 2023, TCBP was notified of non-compliance due to its stock price falling below the $1.00 threshold for 30 consecutive business days.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:41 pm

TC BioPharm's stock price is down following the announcement of cost-cutting measures, which include a significant reduction of its workforce by 50%.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 6:38 pm

SoFi Technologies, Inc. (SOFI) shares dropped by approximately 13% after Keefe, Bruyette & Woods downgraded the stock from Market Perform to Underperform and reduced the price target from $7.50 to $6.50. The downgrade was based on recent outperformance and changes in the analyst's model. Other stocks experienced significant movements in Wednesday's mid-day session, with various companies reporting gains due to positive developments such as regulatory approvals, partnership announcements, and favorable analyst ratings. Conversely, some stocks saw declines due to negative news such as poor earnings, strategic setbacks, or unfavorable analyst actions.

Portfolio Pulse from Avi Kapoor

January 03, 2024 | 5:58 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.